Foghorn Therapeutics (FHTX) Other Accumulated Expenses (2020 - 2026)
Foghorn Therapeutics' quarterly Other Accumulated Expenses came in at $437000.0 in Q1 2026, down 16.92% year-on-year from $526000.0 in Q1 2025, and up 9.25% quarter-over-quarter from $400000.0 in Q4 2025.
Foghorn Therapeutics has reported Other Accumulated Expenses for 7 years, with the latest figure at $437000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses fell 16.92% year-over-year to $437000.0; the trailing twelve-month figure through Mar 2026 stood at $437000.0 (down 16.92% YoY), and the FY2025 full-year result was $400000.0, up 39900.0% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $437000.0, up from $400000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $526000.0 in Q1 2025, with the low at $1000.0 in Q4 2024.
- Average Other Accumulated Expenses over 5 years is $269625.0, with a median of $286500.0 recorded in 2022.
- Year-over-year, Other Accumulated Expenses plunged 97.22% in 2024 and soared 39900.0% in 2025.
- Tracing FHTX's Other Accumulated Expenses over 5 years: stood at $318000.0 in 2022, then plunged by 88.68% to $36000.0 in 2023, then sank by 97.22% to $1000.0 in 2024, then soared by 39900.0% to $400000.0 in 2025, then advanced by 9.25% to $437000.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $437000.0 (Q1 2026), $400000.0 (Q4 2025), and $396000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Foghorn Therapeutics | 297.63 Mn | 208.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 437,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 396,000.00 |
| Jun 30, 2025 | 392,000.00 |
| Mar 31, 2025 | 526,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 213,000.00 |
| Jun 30, 2024 | 239,000.00 |
| Dec 31, 2023 | 36,000.00 |
| Sep 30, 2023 | 301,000.00 |
| Jun 30, 2023 | 94,000.00 |
| Mar 31, 2023 | 135,000.00 |
| Dec 31, 2022 | 318,000.00 |
| Sep 30, 2022 | 324,000.00 |
| Jun 30, 2022 | 272,000.00 |
| Mar 31, 2022 | 230,000.00 |
| Dec 31, 2021 | 392,000.00 |
| Sep 30, 2021 | 108,000.00 |
| Dec 31, 2020 | 138,000.00 |